AT509493A5 - Feste arzneiform von olmesartan medoxomil und amlodipin - Google Patents

Feste arzneiform von olmesartan medoxomil und amlodipin Download PDF

Info

Publication number
AT509493A5
AT509493A5 AT0939307A AT93932007A AT509493A5 AT 509493 A5 AT509493 A5 AT 509493A5 AT 0939307 A AT0939307 A AT 0939307A AT 93932007 A AT93932007 A AT 93932007A AT 509493 A5 AT509493 A5 AT 509493A5
Authority
AT
Austria
Prior art keywords
amlodipin
olmesartan medoxomil
solid medicament
medicament
solid
Prior art date
Application number
AT0939307A
Other languages
English (en)
Other versions
AT509493B1 (de
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38754721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT509493(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of AT509493A5 publication Critical patent/AT509493A5/de
Application granted granted Critical
Publication of AT509493B1 publication Critical patent/AT509493B1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT0939307A 2006-09-15 2007-10-12 Feste arzneiform von olmesartan medoxomil und amlodipin AT509493B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84509006P 2006-09-15 2006-09-15
PCT/GB2007/003933 WO2008032107A1 (en) 2006-09-15 2007-10-12 Solid dosage form of olmesartan medoxomil and amlodipine

Publications (2)

Publication Number Publication Date
AT509493A5 true AT509493A5 (de) 2011-09-15
AT509493B1 AT509493B1 (de) 2012-01-15

Family

ID=38754721

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0939307A AT509493B1 (de) 2006-09-15 2007-10-12 Feste arzneiform von olmesartan medoxomil und amlodipin

Country Status (22)

Country Link
US (2) US20090175942A1 (de)
JP (1) JP5344620B2 (de)
AT (1) AT509493B1 (de)
AU (1) AU2007297333B2 (de)
BR (1) BRPI0716893A2 (de)
CH (1) CH703897B1 (de)
DE (1) DE212007000063U1 (de)
DK (1) DK200900369A (de)
FI (1) FI124122B (de)
GB (1) GB2454620B (de)
IL (1) IL197518A0 (de)
IS (1) IS8808A (de)
MY (1) MY157716A (de)
NZ (1) NZ575422A (de)
PT (1) PT2008032107W (de)
RU (1) RU2423975C2 (de)
SE (1) SE0900332L (de)
SK (1) SK288460B6 (de)
TR (1) TR200901984T1 (de)
TW (1) TWI399223B (de)
WO (1) WO2008032107A1 (de)
ZA (1) ZA200810616B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2598449Y2 (ja) 1993-08-06 1999-08-09 株式会社ソミック石川 ボールジョイント
ES2510866T3 (es) 2008-03-13 2014-10-21 Daiichi Sankyo Company, Limited Mejora de la solubilidad de una preparación que contiene olmesartán medoxomilo
TW201000097A (en) * 2008-05-30 2010-01-01 Daiichi Sankyo Co Ltd Medicament for the prophylaxis or treament of hypertension
US20120115837A1 (en) * 2009-04-30 2012-05-10 Takeda Pharmaceutical Company Limited Solid Preparation
SI2538924T1 (sl) * 2010-02-24 2014-09-30 Sanofi-Aventis Deutschland Gmbh Trdne farmacevtske formulacije ramiprila in amlodipin bezilata in njihova priprava
EP2425859A1 (de) * 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Formulationen von Olmesartan
CN102028663B (zh) * 2010-12-14 2011-11-30 北京万生药业有限责任公司 一种稳定的奥美沙坦酯固体制剂
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
CN103565807B (zh) * 2012-07-25 2015-11-04 天津市汉康医药生物技术有限公司 一种奥美沙坦酯氨氯地平药物组合物
JP5790965B2 (ja) * 2012-10-12 2015-10-07 味の素株式会社 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法
JP5871984B2 (ja) * 2013-04-15 2016-03-01 株式会社三和化学研究所 オルメサルタンメドキソミルを含有する医薬組成物
WO2014188729A1 (ja) * 2013-05-24 2014-11-27 持田製薬株式会社 経口用組成物
EP2883539A1 (de) 2013-12-12 2015-06-17 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmazeutische Kombinationen aus Olmesartan und Amlodipin
CN104739799B (zh) * 2013-12-27 2018-01-05 辰欣药业股份有限公司 一种用于直接压片的苯磺酸氨氯地平组合物及其片剂制备方法
KR102222917B1 (ko) * 2014-06-25 2021-03-05 한림제약(주) 암로디핀 및 올메사탄 메독소밀을 포함하는 약학 조성물
CN104997778A (zh) * 2015-07-08 2015-10-28 南京正大天晴制药有限公司 一种奥美沙坦酯氨氯地平药物组合物
CN105902510A (zh) * 2015-12-24 2016-08-31 嘉实（湖南）医药科技有限公司 一种奥美沙坦酯氨氯地平复方制剂的制备工艺
MX2021010183A (es) 2019-02-26 2021-09-21 Daewoong Pharmaceutical Co Ltd Composicion farmaceutica con forma de dosificacion unica para tratar o prevenir la hipertension y la hiperlipidemia.
CN115300476B (zh) * 2022-09-01 2024-04-16 华润双鹤药业股份有限公司 一种药物组合物及其制备方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3025292A (en) 1962-03-13 Reduction of i
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4772596A (en) * 1986-10-09 1988-09-20 Sankyo Company Limited Dihydropyridine derivatives, their preparation and their use
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5260285A (en) * 1990-12-07 1993-11-09 Merck & Co., Inc. Substituted imidazopyridazines as angiotensin II antagonists
US5250521A (en) * 1990-12-07 1993-10-05 Merck & Co., Inc. Substituted pyrazolopyrimidines as angiotensin II antagonists
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5238942A (en) * 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
JPH05967A (ja) * 1991-06-19 1993-01-08 Yamanouchi Pharmaceut Co Ltd 組織プラスミノーゲンアクチベーター含有製剤組成物
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
FR2688781B1 (fr) * 1992-03-23 1994-07-01 Sanofi Elf Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
US5312820A (en) * 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
GB9405833D0 (en) * 1994-03-24 1994-05-11 Pfizer Ltd Separation of the enantiomers of amlodipine
US5952006A (en) * 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6036977A (en) * 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
US5808084A (en) * 1996-02-14 1998-09-15 Pfizer, Inc. Process for the preparation of 1,4-dihydropyridinedicarboxylic esters
EP0795327A1 (de) * 1996-03-13 1997-09-17 Pfizer Inc. Verwendung von Amlodipin zur Behandlung von Prophylaxe von kongestivem Herzversagen nichtischämischen Ursprungs
US6420412B2 (en) * 1996-03-29 2002-07-16 Smithkline Beecham Corporation Eprosartan dihydate and a process for its production and formulation
CN1221259C (zh) * 1996-07-15 2005-10-05 三共株式会社 Cs－866、氯沙坦和坎迪沙坦用于制备治疗动脉硬化的药物
DE69807695T2 (de) * 1997-06-27 2003-07-31 Smithkline Beecham Corp., Philadelphia Eprosartan-monohydrate
US6630498B2 (en) * 1997-08-06 2003-10-07 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
US20010044584A1 (en) * 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US20030022928A1 (en) * 1998-03-11 2003-01-30 Smithkline Beecham Corporation Novel compositions of eprosartan
US20020127254A1 (en) * 1998-06-25 2002-09-12 Lavipharm Laboratories Inc. Devices for local and systemic delivery of active substance and methods of manufacturing thereof
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
EP1867342A1 (de) * 1999-07-21 2007-12-19 Takeda Pharmaceutical Company Limited Wirkstoffe zum Lindern von Beschwerden infolge von zerebrovaskulären Erkrankungen und zum Hemmen deren Fortschreitens
SK2692002A3 (en) * 1999-08-30 2002-07-02 Aventis Pharma Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
DE60128683T2 (de) * 2000-04-11 2008-01-24 Sankyo Co., Ltd. Stabilisierte pharmazeutische zusammenstellungen die den calziumkanalblocker azelnidipine enthalten
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
CA2420844A1 (en) * 2000-08-30 2003-02-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
EP1353727A2 (de) * 2000-12-01 2003-10-22 Novartis AG Kombinationen eines angiotensinrezeptor-hemmers und eines antihypertensiven medikaments oder eines statins, zur behandlung sexueller funktionsstörungen
US20030138494A1 (en) * 2001-05-15 2003-07-24 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
CA2456034A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
US6680334B2 (en) * 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
EP1438027A1 (de) * 2001-10-25 2004-07-21 DepoMed, Inc. Behandlungsmethode unter verwendung einer losartan enthaltenden darreichungsform mit verlängerter magenverweilzeit
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
AU2004208615C1 (en) * 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
HUP0301537A3 (en) * 2003-06-03 2005-07-28 Egis Gyogyszergyar Nyilvanosan Deramcyclane fumarate tablets and process for producing them
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
WO2005070462A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
US20060074117A1 (en) * 2004-09-02 2006-04-06 Lilach Hedvati Purification of olmesartan medoxomil
JP2006176496A (ja) * 2004-11-24 2006-07-06 Freunt Ind Co Ltd 固形剤およびその製造方法
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
KR20090108739A (ko) * 2005-01-03 2009-10-16 테바 파마슈티컬 인더스트리즈 리미티드 불순물의 양이 감소된 올메사탄 메독소밀
WO2006115834A1 (en) * 2005-04-20 2006-11-02 Merck & Co., Inc. Angiotensin ii receptor antagonists
TWI407978B (zh) * 2005-06-27 2013-09-11 Sankyo Co 濕粒狀藥物之製備方法
TWI405580B (zh) * 2005-06-27 2013-08-21 Sankyo Co 含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物
KR20070009851A (ko) * 2005-07-14 2007-01-19 씨제이 주식회사 클로피도그렐 황산수소염 함유 약학 조성물
WO2007031933A2 (en) * 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
US20090215744A1 (en) * 2005-11-18 2009-08-27 Astrazeneca Ab Solid Formulations
JP2007145646A (ja) * 2005-11-28 2007-06-14 Asahi Glass Co Ltd プレス成型装置及びプレス成型装置の搬送品搬送方法
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.

Also Published As

Publication number Publication date
TW200817052A (en) 2008-04-16
US20090175942A1 (en) 2009-07-09
ZA200810616B (en) 2009-08-26
GB2454620A (en) 2009-05-13
GB0903844D0 (en) 2009-04-22
WO2008032107A1 (en) 2008-03-20
CH703897B1 (de) 2012-04-13
TWI399223B (zh) 2013-06-21
MY157716A (en) 2016-07-15
FI20090094L (fi) 2009-03-13
SE0900332L (sv) 2009-06-12
RU2009114166A (ru) 2010-10-20
JP2011500505A (ja) 2011-01-06
AU2007297333A1 (en) 2008-03-20
IL197518A0 (en) 2009-12-24
DE212007000063U1 (de) 2009-05-14
US20160129008A1 (en) 2016-05-12
TR200901984T1 (tr) 2009-08-21
HK1127282A1 (en) 2009-09-25
JP5344620B2 (ja) 2013-11-20
SK50212009A3 (sk) 2009-06-05
DK200900369A (en) 2009-03-16
SK288460B6 (sk) 2017-03-01
NZ575422A (en) 2011-01-28
PT2008032107W (pt) 2013-07-09
AT509493B1 (de) 2012-01-15
AU2007297333B2 (en) 2010-10-28
BRPI0716893A2 (pt) 2014-05-06
GB2454620B (en) 2011-08-17
FI124122B (fi) 2014-03-31
RU2423975C2 (ru) 2011-07-20
IS8808A (is) 2009-03-12

Similar Documents

Publication Publication Date Title
AT509493A5 (de) Feste arzneiform von olmesartan medoxomil und amlodipin
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
EP2094085A4 (de) Anti-cholesterin-verbindungen und anwendungsverfahren dafür
ATE488227T1 (de) Feste zubereitung mit alogliptin und pioglitazon
EP2037917A4 (de) Pharmazeutische zusammensetzung mit amlodipin und losartan
ATE511509T1 (de) Azaindolylverbindungen und anwendungsverfahren
EP2083864A4 (de) Antagonisten von pcsk9
EP2083859A4 (de) Pcsk9-antagonisten
EP2083860A4 (de) Pcsk9-antagonisten
NO345064B1 (no) Anvendelse av kombinasjonslegemidler, omfattende antimykotika
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
EP2068864A4 (de) Therapeutische verwendungen von urolithinen
EP1998737A4 (de) Körperpflege- und dermatologische zusammensetzungen
EP1891597A4 (de) Vereinigte verwaltung von abgabe, verabreichung und abbildung von radiopharmazeutika
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0819232A2 (pt) composto heterocíclico e composição farmacêutica do mesmo
IL181549A0 (en) Preparation of olmesartan medoxomil
EP2079544A4 (de) Arsenabsorbierende zusammensetzung und verwendungsverfahren
EP2154966A4 (de) Benzimidazole und pharmazeutische zusammensetzungen daraus
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
BRPI0920647A2 (pt) composto de piperidina e composição farmacêutica e respectivo uso e método de tratamento de doença gastrointestinal em mamífero
EP2141160A4 (de) Zerriebener kristall von olmesartanmedoxomil
EP2341047A4 (de) Cyclohexanderivat und pharmazeutische anwendung davon
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto
EP1950188A4 (de) Piezoelektrische keramikzusammensetzung und piezoelektrische keramik